Pursuit Vascular is close to reaching a $1.6 million funding goal, having raised $1.57 million, according to a regulatory filing.

Minneapolis-based Pursuit Vascular is devleoping technology for reducing catheter infections, including the ClearGuard platform that’s designed to cut infections associated with hemodialysis catheters.

Pursuit said 39 unnamed backers participated in the equity round, which kicked off Feb. 4, with a minimum commitment of $3,000 per investor, according to the filing.

Some $400,000 from the proceeds is slated for executive salaries, according to the filing.